Results

1–6 of 6 results for non-neovascular AMD clinical trials

LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019
Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017